SERB Pharmaceuticals to acquire Y-mAbs Therapeutics for $412m.

SERB Pharmaceuticals, a global specialty pharmaceutical company, agreed to acquire Y-mAbs Therapeutics, a biopharmaceutical company that focuses on the development and commercialization of novel antibody-based therapeutic products, for $412m. “Our Board regularly reviews our business, including our strategy, the current state of the biopharmaceutical sector and the time and resources required to execute on our strategic plans. Following the thorough process to explore all of the potential paths forward for the Company, we are now moving forward with this agreement with SERB that we believe reflects the most attractive option available to Y-mAbs, providing significant, immediate and certain value to our stockholders,” Michael Rossi, President, Y-mAbs CEO and Board Member.